Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1% – What’s Next?

Denali Therapeutics Inc. (NASDAQ:DNLI) traded up 6.1% during mid-day trading on Monday . The stock traded as high as $21.23 and last traded at $20.89. 544,351 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 1,636,371 shares. The stock had previously closed at $19.69.

Wall Street Analyst Weigh In

DNLI has been the topic of a number of recent analyst reports. Wolfe Research started coverage on shares of Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. BTIG Research upped their price objective on shares of Denali Therapeutics from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a research note on Monday, November 17th. UBS Group started coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research note on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.20.

Denali Therapeutics Stock Up 0.6%

The company has a market capitalization of $3.40 billion, a PE ratio of -7.22 and a beta of 1.02. The stock’s fifty day moving average is $19.59 and its two-hundred day moving average is $17.40. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the company posted ($0.67) EPS. As a group, analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the sale, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This trade represents a 5.74% decrease in their position. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DNLI. AlphaQuest LLC boosted its position in Denali Therapeutics by 224.1% during the third quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock worth $1,081,000 after purchasing an additional 51,458 shares during the period. Aberdeen Group plc raised its position in shares of Denali Therapeutics by 23.4% in the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after purchasing an additional 210,835 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Denali Therapeutics by 18.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock valued at $18,458,000 after buying an additional 198,207 shares in the last quarter. Schroder Investment Management Group boosted its holdings in Denali Therapeutics by 32.5% in the 2nd quarter. Schroder Investment Management Group now owns 386,539 shares of the company’s stock worth $5,408,000 after buying an additional 94,744 shares during the period. Finally, Campbell & CO Investment Adviser LLC boosted its holdings in Denali Therapeutics by 51.9% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 216,774 shares of the company’s stock worth $3,148,000 after buying an additional 74,066 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.